

## **ATTORNEY DOCKET 1276-37**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kannan et al.

Examiner: Not yet known

Serial No.:

10/762,180

Group Art Unit: 1615

Filed:

January 21, 2004

Date: February 7, 2005

For:

CONTROLLED RELEASE MODIFYING COMPLEX

AND PHARMACEUTICAL COMPOSITIONS THEREOF

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Applicant(s) duty of disclosure, the information listed on the attached form PTO-1449 is brought to the attention of the Examiner.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to a substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

## CERTIFICATION UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: February 7, 2005

Jalerie I Senatore

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

The references were cited in a Search Report received from the International Searching Authority in corresponding PCT Application No. PCT/IB04/00274 received from the International Searching Authority, dated January 25, 2005. Applicants are submitting a copy of the International Search Report. The relevance of the references have been described in the Search Report.

Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account <u>04-1121</u>. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. <u>04-1121</u> therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguishable over the prior art and to be in condition for allowance.

Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,

Michael E. Carmer Reg. No. 43,533

Attorney for Applicants

DILWORTH & BARRESE, LLP 333 Earle Ovington Blvd. Uniondale, NY 11553 (516) 228-8484 (516) 228-8516 (fax)

Form PTO-14	449	U.S. DEPART PATENT ANI	MENT OF COMMERCE TRACEMARK OFFICE	ATTY. DOCKET NO. 1276-37		SERIAL NO. 10/762,180		
	INFO	DRMATION DISCLO	OSURE FEB 0 9 2005 8	APPLICANT Kannan, et al.				
ST (Use		DRMATION DISCLO TEMENT BY APPLI several sheets if nec	CANS TRADEALINE	FILING DATE January 21, 2004		GROUP ART UNIT 1615		
				ENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLA		S SUBCLASS	FILING DATE IF APPROPRIATE	
		4,966,768	10/30/1990 N	Aichelucci et al.				
	1 13	5,273,758	12/28/1993 F	Royce	6.4			
		6,117,453	09/12/2000 S	Seth et al.				
							l	-
			FOREIGN P	ATENT DOCUMENTS	<del>- 1 **</del>			
		DOCUMENT	DATE	COUNTRY	CLASS	S SUBCLASS	TRANSLATION	
		NUMBER					YES	NO
		OTHE	ER PRIOR ART (Including	Author, Title, Date, Pertine	nt Pages, E	tc.)		
		( -, li-		<del></del>	÷			- 7
				200-00-	···			
				And the second s				
EXAMINER			DATE CONSIDERED					
				n is in conformance with MP this form with next commun				

(Form PTO-1449 [6-4])